Initial experience of the safety and tolerability of the BNT162b2 (Pfizer-Bio-N-Tech) vaccine in extremely vulnerable children aged 12–15 years. Issue 2 (26th August 2021) - King, Hayley; Deshpande, Sanjay; Woodbridge, Tamsin; Hilliard, Tom; Standing, Jon; Lewis, Mary; Ward, Lesley; Finn, Adam; Roderick, Marion